[1]阴铭迪,李 林.前列腺癌实验室诊断的最新进展[J].现代检验医学杂志,2022,37(05):194-198.[doi:10.3969/j.issn.1671-7414.2022.05.039]
　YIN Ming-di,LI Lin.Recent Advances in Laboratory Diagnosis of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2022,37(05):194-198.[doi:10.3969/j.issn.1671-7414.2022.05.039]
点击复制

前列腺癌实验室诊断的最新进展()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年05期
页码:
194-198
栏目:
综述
出版日期:
2022-09-15

文章信息/Info

Title:
Recent Advances in Laboratory Diagnosis of Prostate Cancer
文章编号:
1671-7414（2022）05-194-05
作者:
阴铭迪1; 李 林2
1. 陕西中医药大学, 陕西咸阳712046；2. 陕西省肿瘤医院, 西安 710061
Author(s):
YIN Ming-di1; LI Lin2
1.Shaanxi University of Chinese Medicine, Shaanxi Xianyang 712046, China; 2.Shaanxi Provincial Cancer Hospital，Xi’an 710061, China
关键词:
前列腺癌; 前列腺特异性抗原同源异构体2; 前列腺癌基因3; 基因融合; 启动子甲基化
分类号:
R737.25；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.05.039
文献标志码:
A
摘要:
用于实验室检查前列腺癌（prostate cancer, PCa）的前列腺特异性抗原（prostate-specific antigen, PSA）已无法满足临床的需求，目前急需新型的前列腺癌标志物来诊断和检测前列腺癌的发生、发展和预后。随着研究的深入众多，新型前列腺癌标志物在不同方面都体现了各自的优势，同时又存在其不足。该文通过广泛查阅最新的资料，比较各个指标的诊断效能、优缺点及目前临床应用的情况，探讨前列腺癌实验室诊断的最新进展，寻找能够加强前列腺癌的诊断效能的新方法，以期为患者提供更加高效的治疗手段。
Abstract:
Prostate-specific antigen (PSA) used for laboratory examination of prostate cancer has been unable to meet the clinical needs, and new markers of prostate cancer(PCa) are urgently needed to diagnose and detect the occurrence, development and prognosis of prostate cancer. With the deepening of research, many new prostate cancer markers have their advantages in different aspects, but also have their disadvantages. Through extensive access to the latest data, this paper compares the diagnostic efficacy, advantages and disadvantages of each indicator and the current clinical application situation, discusses the latest progress of laboratory diagnosis of prostate cancer, and looks for new methods that can enhance the diagnostic efficacy of prostate cancer, in order to provide more efficient treatment for patients.

参考文献/References:

[1] FREDJ Z, BEN ALI M B, ABBAS M N, et al.Determination of prostate cancer biomarker acid phosphatase at a copper phthalocyanine modified screen printed gold transducer[J]. Analytica Chimica Acta, 2019, 1057:98-105.
[2] 黄汝杭, 陈志远, 周懂晶, 等. 探讨前列腺酸性磷酸酶联合MRI 对前列腺癌的诊断作用[J]. 现代医用影像学, 2018,27(3):741-742, 745.
HUANG Ruhang,CHEN Zhiyuan,ZHOU Dongjing,et al.To investigate the diagnostic value of prostate acid phosphatase combined with MRI in prostate cancer[J].Modern Medical Imageology,2018,27(3):741-742, 745.
[3] 王祥卫, 张志宏. TrACP 在诊断和预测前列腺癌骨转移中的临床意义[J]. 局解手术学杂志, 2015, 24(5): 510-512.
WANG Xiangwei,ZHANG Zhihong.Clinical significance of TrACP in diagnosis and prediction of bone metastasis in prostate cancer[J].Journal of Regional Anatomy and Operative Surgery, 2015,24(5):510-512.
[4] 贾伟, 吴波, 陈骞, 等. 前列腺健康指数及f/tPSA 对于PSA“灰区”前列腺癌诊断价值比较的Meta 分析[J]. 中华腔镜泌尿外科杂志(电子版), 2021, 15 (6):478-483.
JIA Wei,WU Bo,CHEN Qian,et al.Prostate health index versus free/total PSA for prostate cancer detection in patients with PSA levels in “gray area”: a systematic analysis[J].Chinese Journal of Endourology(Electronic Edition), 2021, 15(6):478-483.
[5] 付贤, 何华东, 王于勇, 等. 血PSA，MRI 和超声造影联合应用在前列腺癌中的诊断价值[J]. 实用肿瘤杂志, 2018, 33 (6):529-532.
FU Xian,HE Huadong,WANG Yuyong,et al.Value of combined usage of PSA, MRI and contrast-enhanced ultrasonography in diagnosis of prostate cancer[J].Journal of Practical Oncology,2018,33(6):529-532.
[6] CHENG Y T, HUANG C Y, CHEN C H, et al.Preoperative %p2PSA and prostate health index predict pathological outcomes in patients with prostate cancer undergoing radical prostatectomy[J]. Scientific Reports,2020, 10(1):776.
[7] OTHMAN H, ABU YAMIN AH, MD ISA N, et al.Diagnostic performance of prostate health index (PHI) in predicting prostate cancer on prostate biopsy[J].Malaysian Journal of Pathology, 2020,42(2):209-214.
[8] S R I P L A K I C H S , L O J A N A P I WAT B ,CHONGRUKSUT W, et al. Prospective performance of the prostate health index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4–10 ng/ml and negative digital rectal examination[J]. Prostate International,2018,6(4):136-139.
[9] 潘良明, 沈菲菲, 马晓英, 等. 血清前列腺健康指数对tPSA 灰区前列腺癌患者的诊断价值探讨[J]. 现代检验医学杂志, 2021,36(1):72-76, 99.
PAN Liangming,SHEN Feifei, MA Xiaoying,et al.Diagnostic value of serum prostate health index in prostate cancer patients with PSA gray area[J].Journal of Modern Laboratory Medicine, 2021, 36(1):72-76,99.
[10] HSIEH P, LI Weijuan, LIN Weiching, et al. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population[J].World Journal of Urology, 2020,38(5):1207-1214.
[11] 胡司琦, 张勇. 68Ga-PSMA-11 与18F-PSMA-1007在前列腺癌中的应用[J]. 新医学, 2022,53(1):5-9.
HU Siqi, ZHANG Yong.Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer[J]. Journal of New Medicine, 2022, 53(1): 5-9.
[12] 陈肖玥, 戴军, 程然, 等. 18F-PSMA 联合18F-FDG双核素PET/MR 显像对前列腺癌术前评估的临床价值[J]. 中国临床医学影像杂志, 2021,32(12):876-883.
CHEN Xiaoyue, DAI Jun, CHENG Ran, et al. Clinical value of 18F-PSMA and 18F-FDG dual-nuclide PET/MR imaging in preoperative evaluation of prostate cancer[J].Journal China Clinic Medical Imaging, 2021,32 (12):876-883.
[13] 陈培, 邓钦木, 李丹丹. 血浆Septin9 甲基化检测在结直肠癌中的诊断价值[J]. 现代检验医学杂志,2020, 35(4):10-13.
CHEN Pei, DENG Qinmu, LI Dandan. Diagnostic value of plasma Septin9 methylation in screening of colorectal cancer[J].Journal of Modern Laboratory Medicine,2020,35(4):10-13.
[14] LEE J J, YANG Hongye, FRANC B L, et al. Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin?) positron emission tomography[J]. European Journal of Nuclear Medicine and Molecular Imaging, 2020,47(13):2992-2997.
[15] ZHOU Xueliang, JIAO Dechao, DOU Mengmeng, et al. Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis[J].Journal of cancer research and clinical oncology,2019,145(8):1939-1948.
[16] SANTRIC V, DRAGICEVIC D, MATIC M, et al. Polymorphisms in genes encoding glutathione transferase pi and glutathione transferase omega influence prostate cancer risk and prognosis[J].Frontiers in Molecular Biosciences, 2021,8:620690.
[17] BOSE R, KARTHAUS W R, ARMENIA J, et al. ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis[J]. Nature, 2017,546(7660):671-675.
[18] REZATABAR S, MOUDI E, SADEGHI F, et al.Evaluation of the plasma level of long non‐coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients[J]. The Journal of Gene Medicine, 2020, 22(10):e3239.
[19] MEHRA R, UDAGER A M, AHEARN T U, et al.Overexpression of the long non-coding RNA SChLAP1 Independently predicts lethal prostate cancer[J].European Urology, 2016,70(4):549-552.
[20] LI Ye, LUO Haihong, XIAO Nan, et al. Long noncoding RNA SChLAP1 accelerates the proliferation and metastasis of prostate cancer via targeting miR-198 and promoting the MAPK1 pathway[J]. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics, 2018,26(1):131-143.
[21] DAI Xiaofen, LIANG Zuowen, LIU Lingyun, et al.Silencing of MALAT1 inhibits migration and invasion by sponging miR-1-3p in prostate cancer cells[J].Molecular medicine reports, 2019,20(4):3499-3508.
[22] FERRI C, DI BIASE A, BOCCHETTI M, et al. MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer[J]. Journal of Experimental & Clinical Cancer Research, 2022, 41(1):20.
[23] JIANG Hao, DENG Wen, ZHU Ke, et al. LINC00467 promotes prostate cancer progression via M2 macrophage polarization and the miR-494-3p/STAT3 axis[J]. Front Oncol, 2021,11:661431.
[24] 张可, 蒋伟, 黎卓君, 等. 尿液前列腺癌基因（PCA3）联合多参数磁共振对前列腺癌的诊断价值[J]. 中华腔镜泌尿外科杂志( 电子版), 2021,15(6): 463-466.
ZHANG Ke, JIANG Wei, LI Zhuojun,et al.A pilot study on urinary PCA3 combined with multiparametric MRI for the diagnosis of prostate cancer[J].Chinese Jounal Endourology(Electronic Edition), 2021,15(6):463-466.
[25] LI Meifeng, ZHOU Dong, ZHANG Weili, et al. Urine PCA3 mRNA level in diagnostic of prostate cancer[J].Journal of Cancer Research and Therapeutics, 2018, 14(4): 864-866.
[26] HTOO K P P, YAMKAMON V, YAINOY S, et al.Colorimetric detection of PCA3 in urine for prostate cancer diagnosis using thiol-labeled PCR primer and unmodified gold nanoparticles[J]. Clinica Chimica Acta, 2019,488:40-49.
[27] 闫瑾, 李小珍, 杨飞. 外周血前列腺癌抗原3 基因检测对前列腺癌诊断的meta 分析[J]. 现代检验医学,2019,34(5):40-44, 51.
YAN Jin,LI Xiaozhen,YANG Fei.Validity of PCA3 gene test in peripheral blood for prostate cancer diagnosis:a meta-analysis[J].Journal of Modern Laboratory Medicine, 2019, 34(5):40-44, 51.
[28] ASKARI M, YAZDANI A, YAZDANI M, et al. Serum levels of total and urine level of PCA3 in patients with benign prostatic hyperplasia and prostate cancer[J].American Journal of Clinical and Experimental Urology, 2020, 8(1):43-47.
[29] ALSHALALFA M, VERHAEGH G W, GIBB E A, et al. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12 076 patients[J]. Oncotarget,2017,8(31):50804-50813.
[30] 陈鹏, 姜雪燕. PCA3 评估前列腺癌治疗效果的临床研究[J]. 中西医结合心血管病电子杂志, 2020, 8 (2):85, 100.
CHEN Peng,JIANG Xueyan.Clinical study of PCA3 to evaluate the therapeutic effect of prostate cancer[J].Cardiovascular Disease Electronic Journal of integrated traditional Chinese and Western Medicine(Electronic),2020, 8(2): 85, 100.
[31] MAO Zujie, JI Alin, YANG Kebing, et al. Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer[J]. Medicine,2018,97(42):e12806.

相似文献/References:

[1]廖洪利,米叶赛尔·阿不都拉.粘着斑激酶在前列腺癌中表达的研究[J].现代检验医学杂志,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
　LIAO Hong-li,MIYESAIER·Abdula.Research on Expression of FAK in Prostate Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(05):132.[doi:10.3969/j.issn.1671-7414.2016.05.038]
[2]范维肖,刁艳君,马越云,等.超速离心法与QIAGEN膜亲和柱法提取前列腺癌细胞培养上清外泌体的方法学比较[J].现代检验医学杂志,2019,34(03):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
　FAN Wei-xiao,DIAO Yan-jun,MA Yue-yun,et al.Comparison of Ultracentrifugation and Membrane Based-Affinity ColumnMethods in Exosome Isolation from Supernatants of Prostate Cancer Cells[J].Journal of Modern Laboratory Medicine,2019,34(05):6.[doi:10.3969/j.issn.1671-7414.2019.03.002]
[3]潘良明,沈菲菲,马晓英,等.血清前列腺健康指数对 tPSA灰区前列腺癌患者的诊断价值探讨[J].现代检验医学杂志,2021,36(01):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
　PAN Liang-ming,SHEN Fei-fei,MA Xiao-ying,et al.Diagnostic Value of Serum Prostate Health Index in Prostate Cancer Patients with PSA Gray Area[J].Journal of Modern Laboratory Medicine,2021,36(05):72.[doi:10.3969/j.issn.1671-7414.2021.01.019]
[4]何　跃,梁　晶,文礼红,等.前列腺癌患者血清IL-17和IL-35水平表达与临床病理特征以及预后的关系研究[J].现代检验医学杂志,2021,36(04):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
　HE Yue,LIANG Jing,WEN Li-hong,et al.Study on the Relationship between Serum IL-17, IL-35 Levels andClinicopathological Features and Prognosis in Patients with Prostate Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):96.[doi:10.3969/j.issn.1671-7414.2021.04.020]
[5]荣　蓉a,古　颖a,高　翔a,等.前列腺癌组织肝激酶B1，Rab鸟嘌呤核苷酸交换因子-5mRNA表达水平与临床病理特征和预后的相关性研究[J].现代检验医学杂志,2021,36(06):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
　RONG Rong,GU Ying,GAO Xiang,et al.Correlation between the Expression Levels of Liver Kinase B1, Rab Guanine Nucleotide Exchange Factor-5 mRNA in Prostate Cancer Tissues and Its Clinicopathological Characteristics and Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(05):1.[doi:10.3969/j.issn.1671-7414.2021.06.001]
[6]张士保,朱斐煜,谢瑞玉,等.CircRNA-100395 基因通过启动子区甲基化调控miRNA-136-5p/Smad3 轴促进前列腺癌细胞增殖及侵袭的机制研究[J].现代检验医学杂志,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
　ZHANG Shi-bao,ZHU Fei-yu,XIE Rui-yu,et al.Mechanism of CircRNA-100395 Promoter Methylation Promoting Prostate Cancer Cells Proliferation and Invasion by Regulating miRNA-136-5p/Smad3 Axis[J].Journal of Modern Laboratory Medicine,2022,37(05):44.[doi:10.3969/j.issn.1671-7414.2022.05.010]
[7]郑江婷,寸淑娥,尹 冶,等.长链非编码RNA 在前列腺癌治疗抵抗中作用机制的研究进展[J].现代检验医学杂志,2023,38(01):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
　ZHENG Jiang-ting,CUN Shu-e,YIN Ye,et al.Research Progress of Long Non-coding RNA in the Therapeutic Resistance of Prostate Cancer[J].Journal of Modern Laboratory Medicine,2023,38(05):199.[doi:10.3969/j.issn.1671-7414.2023.01.038]
[8]孙 飞,黎春明.基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J].现代检验医学杂志,2023,38(03):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]
　SUN Fei,LI Chun-ming.Prediction of Immunotherapy Effect and Prognosis of Prostate Cancer Based on Immune Cell Tissue Infiltration Immune Score Model[J].Journal of Modern Laboratory Medicine,2023,38(05):189.[doi:10.3969/j.issn.1671-7414.2023.03.035]

备注/Memo

备注/Memo:
基金项目：陕西省科技厅重点研发计划项目（2020SF-170）。
作者简介：阴铭迪（1998-），女，在读硕士，研究方向：临床检验诊断学，E-mail:ltymd1998@sina.com。
通讯作者：李林（1971-），男，主任技师，主要从事医学检验工作，E-mail:489316200@qq.com。
更新日期/Last Update: 2022-09-15